Johnson & Johnson vs Zimmer Biomet Holdings, Inc. — Stock Comparison
Johnson & Johnson (JNJ) and Zimmer Biomet Holdings, Inc. (ZBH) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson narrowly edges Zimmer Biomet Holdings, Inc. on Q·Score (7.1 vs 7 out of 10), led by Quality (9.3 vs 6) and Sentiment (6.9 vs 5). Zimmer Biomet Holdings, Inc. scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst price targets imply similar upside for both: +10.7% for JNJ and +12.2% for ZBH.
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Earnings growing 34% year-over-year on 9% revenue growth.
⚠ cautious analyst consensus — few Buy ratings.
Analyst Consensus
Fundamentals
Frequently Asked Questions
JNJ vs ZBH: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Zimmer Biomet Holdings, Inc. (ZBH) at 7/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: JNJ or ZBH?
Zimmer Biomet Holdings, Inc. (ZBH) scores higher on Growth (8.8/10 vs 5.1/10). Johnson & Johnson reports revenue growth (9.9% YoY) while Zimmer Biomet Holdings, Inc. reports (9.3% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is JNJ or ZBH more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (7.3/10 vs 7.2/10). JNJ trades at 18.0× P/E versus ZBH at 9.8×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about JNJ vs ZBH?
There are 23 analysts covering JNJ with a consensus price target of $252.87, and 20 analysts covering ZBH with a consensus target of $98.70. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: JNJ or ZBH?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 6/10). Net profit margin: JNJ at 21.8%, ZBH at 9.1%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: JNJ or ZBH?
Zimmer Biomet Holdings, Inc. (ZBH) scores higher on Financial Health (7.6/10 vs 6.5/10). Market beta: JNJ at 0.26, ZBH at 0.47. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of JNJ and ZBH?
Johnson & Johnson (JNJ) has a market capitalisation of $549.8B, while Zimmer Biomet Holdings, Inc. (ZBH) has a market cap of $17.0B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do JNJ or ZBH pay dividends?
JNJ pays a dividend yield of 2.35%, while ZBH pays a dividend yield of 1.09%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →